12/15/2020 | DD | Vivus Chapter 11 plan of reorganization effective as of Dec. 11
|
12/10/2020 | DD | Vivus receives confirmation of Chapter 11 plan of reorganization
|
11/18/2020 | DD | Vivus gets 75-day exclusivity extension to finalize settlement terms
|
11/12/2020 | DD | Vivus combined hearing on statement, Chapter 11 plan set for Dec. 3
|
11/5/2020 | DD | Vivus seeks 75-day exclusivity extension to finalize settlement terms
|
10/30/2020 | DD | Vivus, IEH, equity holders’ settlement discussions sent to mediation
|
10/21/2020 | DD | Vivus sets bid procedures for assets; plans to file amended plan
|
9/23/2020 | DD | Vivus: U.S. Trustee appoints official committee of equity holders
|
9/11/2020 | DD | Vivus: U.S. Trustee directed to appoint committee of equity holders
|
8/20/2020 | DD | Vivus plan confirmation and cash use hearings pushed back to Aug. 25
|
8/19/2020 | DD | Vivus plan of reorganization unanimously accepted by voting creditors
|
8/11/2020 | DD | Vivus: U.S. Trustee says plan ‘unduly restricts’ shareholder actions
|
7/13/2020 | DD | Vivus pre-packaged plan confirmation hearing scheduled for Aug. 19
|
7/10/2020 | BKCVDDEMHY | Prospect News reports nine new defaults for week of July 2 to July 8
|
7/9/2020 | DD | Vivus secures emergency court approval of stock trading restrictions
|
7/9/2020 | DD | Vivus seeks court approval to use $21.5 million in cash collateral
|
7/7/2020 | CVDD | Vivus files bankruptcy; plan gives 100% ownership to IEH Biopharma
|
10/3/2019 | LMPV | Vivus pays down $48.6 million of senior secured notes due 2024
|
6/11/2018 | PV | New Issue: Vivus details, wraps $110 million placement of 10.375% notes due 2024
|
5/1/2018 | HYIG | Market Commentary: Vivus sells $110 million of notes; First Bancshares wraps $66 million
|
5/1/2018 | CVLMPV | Vivus buys back $60 million convertibles from Athyrium at discount
|
5/1/2018 | PV | New Issue: Vivus plans to place $110 million 10.375% notes due 2024 with Athyrium
|
10/8/2015 | PP | Market Commentary: SanDisk adds on swap; Icahn gets tenders for 68% of Vivus bonds; SunEdison stays in focus
|
10/8/2015 | CV | Market Commentary: SanDisk adds on swap; Icahn gets tenders for 68% of Vivus bonds; SunEdison stays in focus
|
10/8/2015 | CVLM | Icahn subsidiary obtains tenders for 68% of Vivus’ 4.5% convertibles
|
10/1/2015 | CVLM | Icahn subsidiary affirms cash tender offer for Vivus 4.5% convertibles
|
9/22/2015 | CVLM | Vivus board remains neutral toward Icahn 4.5% convertible tender offer
|
9/10/2015 | CV | Market Commentary: New convertible issues trade mostly in line; Dycom edges up; NextEra pricing overnight
|
9/9/2015 | PP | Market Commentary: Dycom edges up in gray market; BroadSoft bringing new deal; Icahn bid for Vivus eyed
|
9/9/2015 | CV | Market Commentary: Dycom edges up in gray market; BroadSoft bringing new deal; Icahn bid for Vivus eyed
|
9/9/2015 | CV | Market Commentary: Morning Commentary: BroadSoft bringing new deal, buying back existing bonds; Vivus stock surges
|
9/9/2015 | CVLM | Icahn Enterprises tenders for Vivus’ 4.5% convertible notes due 2020
|
5/31/2013 | CV | Vivus greenshoe exercise increases 4.5% convertibles to $250 million
|
5/16/2013 | CV | New Issue: Vivus prices upsized $220 million seven-year convertibles to yield 4.5%, up 15%
|
5/16/2013 | CV | Market Commentary: Vivus quiet on debut; upsized Tesla jumps in gray market, talk tightened; Symantec trades
|
5/15/2013 | CV | Market Commentary: Ryland, Shutterfly gain outright, on hedge on debuts; SunPower jumps; Vivus, Tesla on tap
|
5/15/2013 | CV | Vivus plans $200 million offering of seven-year convertible notes
|
5/15/2013 | CV | Vivus plans to sell $200 million seven-year convertibles to yield 4.25%-4.75%, up 15%-20%
|
4/4/2013 | SP | New Issue: JPMorgan prices $300,000 autocallable contingent interest notes linked to Vivus
|
3/26/2013 | PP | Vivus reports it plans to conduct a $110 million non-equity financing
|
8/23/2011 | PP | Vivus to place $45.8 million shares in registered direct offering
|
8/5/2008 | PP | New Issue: Vivus prices $65 million direct offering of shares
|
4/15/2008 | PP | New Issue: Vivus prices $10 million direct placement of stock
|
11/17/2006 | PP | Market Commentary: BJ's secures $61.5 million from stock sale; Vivus negotiates $33.6 million direct placement of stock
|
11/17/2006 | PP | New Issue: Vivus prices $33.6 million direct placement of stock
|
10/27/2006 | BT | Vivus maintained at outperform by RBC
|
10/26/2006 | BT | Vivus ends quarter with $18.9 million of cash
|
10/20/2006 | BT | Market Commentary: BioVex IPO pulled; Ariad dives; Encysive off; Vical spikes 10%; Amgen higher ahead of results
|
10/2/2006 | BT | Vivus reiterated at outperform by RBC
|
9/6/2006 | BT | Market Commentary: Genta plummets another 41%; Genomic Health falls 17%; Cell Therapeutics up 8%; Anadys up
|
8/17/2006 | BT | Vivus stays at outperform by RBC
|
8/17/2006 | BT | Market Commentary: Neurocrine adds 10%; NPS up on 'Soros factor'; Vivus higher; Genitope slides 4%
|
8/16/2006 | BT | Vivus says larger clinical trials of Qnexa expected to produce positive results
|
7/28/2006 | BT | Vivus maintained at outperform by RBC
|
7/17/2006 | BT | Vivus files $80 million stock shelf
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
6/13/2006 | BT | Market Commentary: Lexicon drops 5%; Genitope stays steady; Vivus, Arena decline amid their respective obesity drug news
|
6/13/2006 | BT | Vivus gets anti-obesity patent
|
6/6/2006 | BT | Vivus at outperform by RBC
|
5/18/2006 | BT | Vivus reports advances among product candidates, expects Qnexa phase 3 trials to start in 2007
|
5/17/2006 | BT | Market Commentary: Vivus up 15%; Hana off 10% on PIPE deal; Restore gains on debut; NxStage drops on follow-on deal
|
5/10/2006 | BT | Market Commentary: Alnylam gains as bird flu names slip; AVI pushes vaccine names lower; Novacea ends flat on debut
|
5/10/2006 | BT | More than half of patients in Qnexa arm of Vivus' phase 2 trial lost 10% or more total body weight
|
5/10/2006 | PP | Market Commentary: Emisphere gears up to wrap $33.04 million stock sale; Vivus to settle $12 million direct offering
|
5/10/2006 | BTPP | New Issue: Vivus secures $12 million from direct stock sale
|
5/5/2006 | BT | Vivus says Evamist spray reduces menopause symptoms by 78%
|
3/1/2006 | BT | Vivus receives key patent for MDTS delivery system
|
12/7/2005 | BT | Vivus completes enrollment of phase 2b trial for Alista to treat female sexual dysfunction
|
11/17/2005 | BT | Vivus announces five positive studies on avanafil presented to Sexual Medicine Society
|
11/1/2005 | BT | Rodman & Renshaw initiates coverage of Vivus
|